Abcam, ab126448, Mek1 (pS217/221) + total Mek1 ELISA Kit

Size: 1 x 96Tests
Mek1 (pS217/221) + total Mek1 ELISA Kit is a Semi-quantitative ELISA for the measurement of Mek1 (pS217/221) + total Mek1 in Human, Mouse, Rat in Cell/Tissue Extracts samples.
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate,
Reacts with:Mouse, Rat, Human,
Assay type:Semi-quantitative,
Assay time:5h,
Assay Platform:Microplate

Product details:
ab126448 is a very rapid, convenient and sensitive assay kit that can monitor the activation or function of important biological pathways in cell lysates. By determining phosphorylated Mek1 protein in your experimental model system, you can verify pathway activation in your cell lysates. You can simultaneously measure numerous different cell lysates without spending excess time and effort in performing a Western Blotting analysis.
This sandwich ELISA kit is an in vitro enzyme-linked immunosorbent assay for the measurement of phospho-Mek1 (Ser217/221) and total Mek1 in human, mouse and rat cell lysates (help normalize the results of phospho-Mek1 from different cell lysate being compared). An anti-pan Mek1 antibody has been coated onto a 96-well plate. Samples are pipetted into the wells and Mek1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and anti-Mek1 (Ser217/221) or anti-pan-Mek1 antibody is used to detect phosphorylated Mek1 (Ser217/221) or total Mek1. After washing away unbound antibody, HRP-conjugated anti-rabbit IgG is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Mek1 (Ser217/221) or total Mek1 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MEK1 also known as MAP2K1 is a dual-specificity kinase that plays a role in the MAPK/ERK pathway. It has a molecular weight of around 45 kDa. MEK1 phosphorylates and activates the extracellular signal-regulated kinases ERK1 and ERK2. MEK1 is expressed in various tissues but is especially abundant in brain and heart tissues. Researchers commonly measure MEK1 levels using techniques like MEK1 ELISA while phospho-MEK antibodies help analyze its activity state.
Biological function summary
MEK1 impacts cell processes such as proliferation differentiation and survival. It does not work alone but forms a complex with other proteins to exert its function. MEK1 activity is tightly controlled by upstream activators and downstream targets. One of the key phosphorylation sites on MEK1 is at serine 298 often marked as MEK1 pS298. This phosphorylation indicates MEK1's activated state which is critical for its biological function.
Pathways
MEK1 integrates signals within the MAPK/ERK pathway and interacts closely with RAF kinases upstream and ERK kinases downstream. This pathway modulates cellular responses to growth factors. MEK1 undergoes phosphorylation enhancing its activity and subsequently phosphorylates ERK proteins. Many studies isolate MEK1 activity using specific inhibitors such as the MEK1 inhibitor to dissect pathway dynamics. ERK inhibitor PD98059 also helps when studying parallel interactions with MEK1.
MEK1 mutations or dysregulation have links to several types of cancer including melanoma. These often involve changes that lead to continuous MEK1 activation contributing to uncontrolled cell growth. MEK1 involvement in the RASopathies also shows its connection to disorders characterized by heart and facial abnormalities. In cancer MEK1 works closely with the BRAF protein which often harbors mutations leading to disease progression showcasing MEK1 as a target for therapeutic intervention.